Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis.
Jia ChenKefei WangZhijian XiaoZefeng XuPublished in: Annals of medicine (2023)
It was confirmed that HMA in combination with venetoclax is an effective and well-tolerated option in MPN-AP/BP patients in pre- as well as post-haematopoietic stem cell transplantation settings. HMA plus ruxolitinib therapy was revealed to be effective in patients with MPN-AP.Key MessagesCombination therapy with HMAs and venetoclax/ruxolitinib was associated with improved outcomes than HMAs alone in MPN-AP/BP patients.Further large-scale randomized controlled trials are needed to confirm regarding to the optimal treatment for this patient population.
Keyphrases
- end stage renal disease
- stem cell transplantation
- chronic kidney disease
- ejection fraction
- randomized controlled trial
- transcription factor
- high dose
- prognostic factors
- acute lymphoblastic leukemia
- clinical trial
- type diabetes
- skeletal muscle
- low dose
- combination therapy
- case report
- systematic review
- patient reported
- smoking cessation
- chronic lymphocytic leukemia
- single cell
- insulin resistance
- cell therapy
- glycemic control